SecurityRGNX / REGENXBIO Inc. (75901B107)
IndustryBiological Products, Except Diagnostic Substances (Biotech)
Common Shares Outstanding32,308,644 shares (as of 2018-06-30)
Total Insiders25
Total Directors11
Total Officers7

Stock Insider Trading (from SEC Form 4)

RGNX / REGENXBIO Inc. Insider Trades

REGENXBIO Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

RGNX / REGENXBIO Inc. insiders include Christmas Patrick J., Mills Kenneth T., Glucksmann Alexandra Tasse Daniel, Ali Faraz, Samuels Camille D, HAYDEN DONALD J JR, Abdun-Nabi Daniel, STUMP DAVID C, Deerfield Mgmt L.P., Vasista Vittal, KARABELAS ARGERIS N, Deerfield Mgmt III, L.P., Danos Olivier, Simpson Curran, DEERFIELD PARTNERS, L.P., Fox Allan M., Flynn James E, FMR LLC / Fidelity Management & Research, Yoo Stephen, DEERFIELD MANAGEMENT CO, Deerfield International Master Fund, L.P., BESHAR LUKE M, ENGLEMAN EDGAR, and Deerfield Private Design Fund III, L.P., .

Insider Roster

Insider Dir Off 10% Shares Owned
Vasista Vittal Chief Financial Officer
X 129,783
Mills Kenneth T. President and CEO, Director
X X 203,530
Christmas Patrick J. SVP, General Counsel
X 17,669
HAYDEN DONALD J JR Director
X 0
KARABELAS ARGERIS N Director
X
Tasse Daniel Director
X
STUMP DAVID C Director
X
Fox Allan M. Director, 10% Owner
X X
BESHAR LUKE M Director
X
Abdun-Nabi Daniel Director
X
Glucksmann Alexandra Director
X
Simpson Curran SVP, Technical Operations
X 39,500
Yoo Stephen Chief Medical Officer
X
Danos Olivier Chief Scientific Officer
X
Ali Faraz Chief Business Officer
X
Samuels Camille D Director
X
FMR LLC / Fidelity Management & Research
Deerfield Mgmt L.P. 10% Owner
DEERFIELD MANAGEMENT CO 10% Owner
Deerfield Mgmt III, L.P. 10% Owner
Deerfield Private Design Fund III, L.P. 10% Owner
Deerfield International Master Fund, L.P. 10% Owner
DEERFIELD PARTNERS, L.P. 10% Owner
Flynn James E 10% Owner
X
ENGLEMAN EDGAR Director
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-07-16 4 Vasista Vittal S X D 77.88 -1,500 129,783 10,107,500
2018-07-16 4 Vasista Vittal S X D 76.60 -862 131,283 10,056,278
2018-07-16 4 Vasista Vittal S X D 75.18 -2,510 132,145 9,934,661
2018-07-16 4 Vasista Vittal S X D 74.19 -2,628 134,655 9,990,054
2018-06-20 4 Mills Kenneth T. S X D 67.66 -750 203,530 13,770,840
2018-06-20 4 Mills Kenneth T. S X D 66.59 -2,650 204,280 13,603,005
2018-06-20 4 Mills Kenneth T. S X D 65.48 -1,300 206,930 13,549,776
2018-06-20 4 Mills Kenneth T. S X D 63.45 -100 208,230 13,212,194
2018-06-20 4 Mills Kenneth T. S X D 61.70 -200 208,330 12,853,961
2018-06-19 4 Christmas Patrick J. M D 12.10 1,528 17,669
2018-06-18 4 Christmas Patrick J. S X D 56.91 -4,600 16,141 918,584
2018-06-18 4 Christmas Patrick J. S X D 55.25 -400 20,741 1,145,940
2018-06-18 4 Christmas Patrick J. M X D 12.10 5,000 21,141
2018-06-15 4 Vasista Vittal S X D 56.90 -4,343 137,283 7,811,403
2018-06-15 4 Vasista Vittal S X D 56.20 -3,157 141,626 7,959,381
2018-06-05 4 HAYDEN DONALD J JR S X D 55.01 -14,900 0
2018-06-05 4 HAYDEN DONALD J JR M X D 0.85 14,900 14,900
2018-06-01 4 HAYDEN DONALD J JR S X D 55.00 -100 0
2018-06-01 4 HAYDEN DONALD J JR M X D 0.85 100 100
2018-05-21 4 Mills Kenneth T. S X D 48.39 -1,401 208,530 10,090,767
2018-05-21 4 Mills Kenneth T. S X D 47.88 -1,800 209,931 10,051,496
2018-05-21 4 Mills Kenneth T. S X D 46.56 -6,799 211,731 9,858,195
2018-05-15 4 HAYDEN DONALD J JR S X D 50.06 -9,847 0
2018-05-15 4 HAYDEN DONALD J JR M X D 0.85 9,847 9,847
2018-05-14 4 HAYDEN DONALD J JR S X D 50.04 -5,153 0
2018-05-14 4 HAYDEN DONALD J JR M X D 0.85 5,153 5,153
2018-05-15 4 Vasista Vittal S X D 50.76 -2,455 144,783 7,349,185
2018-05-15 4 Vasista Vittal S X D 49.93 -3,945 147,238 7,351,593
2018-05-15 4 Vasista Vittal S X D 49.21 -1,100 151,183 7,439,715
2018-05-09 4 HAYDEN DONALD J JR S X D 45.00 -15,000 0
2018-05-09 4 HAYDEN DONALD J JR M X D 0.85 15,000 15,000
2018-05-10 4 Christmas Patrick J. M D 12.10 15,000 16,141
2018-05-09 4 Christmas Patrick J. S X D 44.00 -10,000 1,141 50,204
2018-05-09 4 Christmas Patrick J. S X D 42.00 -5,000 11,141 467,922
2018-05-09 4 Christmas Patrick J. M X D 12.10 15,000 16,141
2018-04-20 4 Mills Kenneth T. S X D 39.93 -900 218,530 8,725,903
2018-04-20 4 Mills Kenneth T. S X D 39.48 -9,100 219,430 8,663,096
2018-04-16 4 Vasista Vittal S X D 37.85 -2,151 152,283 5,763,912
2018-04-16 4 Vasista Vittal S X D 37.34 -2,849 154,434 5,766,566
2018-04-11 4 Christmas Patrick J. S X D 39.00 -10,000 1,141 44,499
2018-04-11 4 Christmas Patrick J. M X D 12.10 10,000 11,141
2018-04-09 4 Christmas Patrick J. S X D 34.00 -10,000 1,141 38,794
2018-04-09 4 Christmas Patrick J. M X D 12.10 10,000 11,141
2018-03-26 4 Vasista Vittal S X D 30.00 -5,000 157,283 4,718,490
2018-03-20 4 Mills Kenneth T. S X D 29.55 -10,000 228,530 6,753,062
2018-03-13 4 Simpson Curran S D 33.00 -25,000 39,500 1,303,500
2018-03-13 4 Simpson Curran M D 22.00 25,000 64,500
2018-03-06 4 Vasista Vittal M D 0.85 60,000 162,283
2018-02-28 4 Vasista Vittal S X D 30.00 -5,000 102,283 3,068,490
2018-02-20 4 Mills Kenneth T. S X D 26.56 -10,000 238,530 6,335,357
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

Related News Stories

REGENXBIO's (RGNX) CEO Ken Mills on Q2 2018 Results - Earnings Call Transcript

2018-08-08 seekingalpha
Good day, ladies and gentlemen, and welcome to REGENXBIO’s Second Quarter 2018 Earnings Conference Call. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will be provided at that time. [Operator Instructions]

ALXN vs. RGNX: Which Stock Is the Better Value Option?

2018-08-06 zacks
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Alexion Pharmaceuticals (ALXN - Free Report) and Regenxbio (RGNX - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. (1-0)

Biotech Stocks Are Tariff-Safe And Building Momentum

2018-07-23 seekingalpha
The Nasdaq Biotechnology Index is poised to make a 52-week high and most likely an all-time high shortly thereafter. (99-1)

ALXN vs. RGNX: Which Stock Is the Better Value Option?

2018-07-19 zacks
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Alexion Pharmaceuticals (ALXN - Free Report) and Regenxbio (RGNX - Free Report) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. (1-0)

ALXN or RGNX: Which Is the Better Value Stock Right Now?

2018-07-19 zacks
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Alexion Pharmaceuticals (ALXN - Free Report) and Regenxbio (RGNX - Free Report) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. (1-0)